Literature DB >> 24464721

Give the receptor a brake: slowing gastric emptying by GLP-1.

Jenny Tong1, David D'Alessio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24464721     DOI： 10.2337/db13-1764

Source DB:  PubMed          Journal:  Diabetes        ISSN： 0012-1797            Impact factor:   9.461


× No keyword cloud information.
  16 in total

1.  MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.

Authors:  Philip D Ambery; Sebastian Klammt; Maximillian G Posch; Marcella Petrone; Wenji Pu; Cristina Rondinone; Lutz Jermutus; Boaz Hirshberg
Journal:  Br J Clin Pharmacol       Date:  2018-08-07       Impact factor: 4.335

2.  An inter-organ neural circuit for appetite suppression.

Authors:  Tong Zhang; Matthew H Perkins; Hao Chang; Wenfei Han; Ivan E de Araujo
Journal:  Cell       Date:  2022-06-02       Impact factor: 66.850

3.  Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.

Authors:  J Miyagawa; M Odawara; T Takamura; N Iwamoto; Y Takita; T Imaoka
Journal:  Diabetes Obes Metab       Date:  2015-08-20       Impact factor: 6.577

Review 4.  Bidirectional Relationship between Gastric Emptying and Plasma Glucose Control in Normoglycemic Individuals and Diabetic Patients.

Authors:  Bogdan Mircea Mihai; Cătălina Mihai; Cristina Cijevschi-Prelipcean; Elena-Daniela Grigorescu; Mihaela Dranga; Vasile Drug; Ioan Sporea; Cristina Mihaela Lăcătușu
Journal:  J Diabetes Res       Date:  2018-10-03       Impact factor: 4.011

5.  Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.

Authors:  Martin B Whyte; Fariba Shojaee-Moradie; Sharaf E Sharaf; Nicola C Jackson; Barbara Fielding; Roman Hovorka; Jeewaka Mendis; David Russell-Jones; A Margot Umpleby
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

6.  Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.

Authors:  Ying Luo; Pijian Yang; Zhengming Li; Yunchen Luo; Jing Shen; Ruwen Li; Hua Zheng; Yuzhen Liang; Ning Xia
Journal:  Drug Des Devel Ther       Date:  2019-12-02       Impact factor: 4.162

7.  Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.

Authors:  Antonino Tuttolomondo; Anna Cirrincione; Alessandra Casuccio; Alessandro Del Cuore; Mario Daidone; Tiziana Di Chiara; Domenico Di Raimondo; Vittoriano Della Corte; Carlo Maida; Irene Simonetta; Stefania Scaglione; Antonio Pinto
Journal:  Cardiovasc Diabetol       Date:  2021-01-04       Impact factor: 9.951

8.  Gastroparesis With the Initiation of Liraglutide: A Case Report.

Authors:  Sami Almustanyir; Habeeb Alhabeeb; Noara AlHusseini; Mohammed Al Thow
Journal:  Cureus       Date:  2020-11-28

9.  GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats.

Authors:  Wijnand J C van der Velden; Florent X Smit; Charlotte B Christiansen; Thor C Møller; Gertrud M Hjortø; Olav Larsen; Sine P Schiellerup; Hans Bräuner-Osborne; Jens J Holst; Bolette Hartmann; Thomas M Frimurer; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-19

10.  Efficacy of metformin on postprandial plasma triglyceride concentration by administration timing in patients with type 2 diabetes mellitus: A randomized cross-over pilot study.

Authors:  Daisuke Sato; Katsutaro Morino; Seiichiro Ogaku; Akiko Tsuji; Kimihiro Nishimura; Osamu Sekine; Satoshi Ugi; Hiroshi Maegawa
Journal:  J Diabetes Investig       Date:  2019-02-22       Impact factor: 4.232
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.